Study the Safety and Effectiveness of MK7009 in Hepatitis C Infected Patients (MK-7009-004)(COMPLETED)
Status and phase
Completed
Phase 1
Conditions
Hepatitis C
Treatments
Drug: Comparator: Placebo
Drug: Comparator: MK7009
Details and patient eligibility
About
The purpose of this study is to investigate the effectiveness, safety, and tolerability of MK7009 in patients infected with Hepatitis C
Enrollment
40 patients
Sex
All
Ages
18 to 55 years old
Volunteers
No Healthy Volunteers
Inclusion criteria
- Subject is a man or a woman aged 18 to 55 years of age.
- Subject has chronic Hepatitis C
- Subject is willing to not use alcohol for 2 weeks prior to therapy and through the study follow-up period
Exclusion criteria
- Patient has evidence of advanced liver disease.
- Patient has human immunodeficiency virus (HIV)
- Patient has Hepatitis B
Trial design
Primary purpose
Treatment
Allocation
Randomized
Interventional model
Parallel Assignment
Masking
Double Blind
40 participants in 8 patient groups
1
Experimental group
Description:
25 mg b.i.d. MK7009
Treatment:
Drug: Comparator: MK7009
2
Experimental group
Description:
75 mg b.i.d. MK7009
Treatment:
Drug: Comparator: MK7009
3
Experimental group
Description:
250 mg b.i.d. MK7009
Treatment:
Drug: Comparator: MK7009
4
Experimental group
Description:
500 mg b.i.d. MK7009
Treatment:
Drug: Comparator: MK7009
5
Experimental group
Description:
700 mg b.i.d. MK7009
Treatment:
Drug: Comparator: MK7009
6
Experimental group
Description:
125 mg q.d. MK7009
Treatment:
Drug: Comparator: MK7009
7
Experimental group
Description:
600 mg q.d. MK7009
Treatment:
Drug: Comparator: MK7009
8
Experimental group
Description:
Placebo
Treatment:
Drug: Comparator: Placebo
Trial contacts and locations
0
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal
© Copyright 2026 Veeva Systems